Literature DB >> 20068165

HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells.

Dianren Xia1, Vijaykumar R Holla, Dingzhi Wang, David G Menter, Raymond N DuBois.   

Abstract

Prostaglandin E(2) (PGE(2)), one of the downstream products of cyclooxygenase-2 enzymatic activity, promotes colorectal carcinogenesis in part by stimulating cell division. In this study, we define a critical mechanism in this process by showing that the prometastatic adapter protein human enhancer of filamentation 1 (HEF1; NEDD9) links PGE(2) to the cell cycle machinery in colorectal cancer cells. PGE(2) rapidly induced expression of HEF1 mRNA and protein in colorectal cancer cells. HEF1 overexpression elicited the same effects as PGE(2) treatment on cell proliferation, cell cycle progression, and tumor growth. Conversely, HEF1 knockdown suppressed PGE(2)-driven cell proliferation and cell cycle progression. Cell cycle alterations involved HEF1 fragmentation as well as co-distribution of HEF1 and cell cycle kinase Aurora A along spindle asters during cell division. Moreover, Aurora A co-immunoprecipitated with HEF1 and was activated by HEF1. Consistent with a role for HEF1 in colorectal carcinogenesis, we found elevated expression of HEF1 expression in 50% of human colorectal cancers examined, relative to paired normal tissues. These findings establish that PGE(2) induces HEF1 expression, which in turn promotes cell cycle progression through its interaction with and activation of Aurora A. Further, they establish that HEF1 is a crucial downstream mediator of PGE(2) action during colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068165      PMCID: PMC2943830          DOI: 10.1158/0008-5472.CAN-09-2105

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  The role of cyclooxygenases in inflammation, cancer, and development.

Authors:  C S Williams; M Mann; R N DuBois
Journal:  Oncogene       Date:  1999-12-20       Impact factor: 9.867

Review 2.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle.

Authors:  Disha Dadke; Michael Jarnik; Elena N Pugacheva; Mahendra K Singh; Erica A Golemis
Journal:  Mol Biol Cell       Date:  2006-01-04       Impact factor: 4.138

4.  Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer.

Authors:  Vijaykumar R Holla; Jason R Mann; Qiong Shi; Raymond N DuBois
Journal:  J Biol Chem       Date:  2005-11-17       Impact factor: 5.157

Review 5.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

6.  The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome.

Authors:  Elena N Pugacheva; Erica A Golemis
Journal:  Nat Cell Biol       Date:  2005-09-25       Impact factor: 28.824

7.  EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways.

Authors:  Sandra Donnini; Federica Finetti; Raffaella Solito; Erika Terzuoli; Andrea Sacchetti; Lucia Morbidelli; Paola Patrignani; Marina Ziche
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

8.  Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer.

Authors:  Jinyi Shao; Chaeyong Jung; Chunming Liu; Hongmiao Sheng
Journal:  J Biol Chem       Date:  2005-05-17       Impact factor: 5.157

9.  Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.

Authors:  Dianren Xia; Harish Srinivas; Young-Ho Ahn; Gautam Sethi; Xiaoyang Sheng; W K Alfred Yung; Qianghua Xia; Paul J Chiao; Heetae Kim; Powel H Brown; Ignacio I Wistuba; Bharat B Aggarwal; Jonathan M Kurie
Journal:  J Biol Chem       Date:  2006-12-11       Impact factor: 5.157

Review 10.  HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks.

Authors:  Elena N Pugacheva; Erica A Golemis
Journal:  Cell Cycle       Date:  2006-02-15       Impact factor: 4.534

View more
  15 in total

1.  Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells.

Authors:  Sun-Hee Kim; Dianren Xia; Sang-Wook Kim; Vijaykumar Holla; David G Menter; Raymond N Dubois
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

2.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression.

Authors:  Y Li; J H Bavarva; Z Wang; J Guo; C Qian; S N Thibodeau; E A Golemis; W Liu
Journal:  Oncogene       Date:  2011-02-14       Impact factor: 9.867

3.  Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.

Authors:  Xiaoling Gu; Yingying Wang; Hua Wang; Qichao Ni; Chunhui Zhang; Jia Zhu; Wei Huang; Pan Xu; Guoxin Mao; Shuyun Yang
Journal:  Med Oncol       Date:  2015-06-02       Impact factor: 3.064

4.  KIF3a promotes proliferation and invasion via Wnt signaling in advanced prostate cancer.

Authors:  Zun Liu; Ryan E Rebowe; Zemin Wang; Yingchun Li; Zehua Wang; John S DePaolo; Jianhui Guo; Chiping Qian; Wanguo Liu
Journal:  Mol Cancer Res       Date:  2014-01-10       Impact factor: 5.852

Review 5.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

6.  High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.

Authors:  Mei Li; Shumei Yan; Muyan Cai; Jiabin Lu; Meifang Zhang; Ping Yang; Rongzhen Luo
Journal:  Mol Clin Oncol       Date:  2015-12-11

7.  Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells.

Authors:  Jin Dai; Peter G Van Wie; Leonard Yenwong Fai; Donghern Kim; Lei Wang; Pratheeshkumar Poyil; Jia Luo; Zhuo Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2016-09-20       Impact factor: 4.219

8.  NEDD9 overexpression correlates with poor prognosis in gastric cancer.

Authors:  Yi Liu; Ding Wang; Kui-Ling Zhao; Jian-Wei Zhu; Hai-Bing Yin; Ying-Ze Wei; Zhi-Jun Wu; Guo-Jian Cheng; Feng Wang; Feng Ni; Xiao-Lin Wang; Guang-Xin Cao; Jian Huang; Jing Cai
Journal:  Tumour Biol       Date:  2014-03-25

9.  NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer.

Authors:  Chenfei Kong; Changqing Wang; Liping Wang; Musong Ma; Chunbo Niu; Xiaoqian Sun; Juan Du; Zhixiong Dong; Shan Zhu; Jun Lu; Baiqu Huang
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

10.  Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation.

Authors:  Chenglin Mo; Ruonan Zhao; Julian Vallejo; Orisa Igwe; Lynda Bonewald; Lori Wetmore; Marco Brotto
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.